VectivBio appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications

VectivBio AG

Arena Pharmaceuticals and Actelion Veteran Brings Deep Industry Experience as VectivBio Prepares for Key Catalysts Ahead

BASEL, Switzerland, April 21, 2022 (GLOBE NEWSWIRE) — VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering new transformational treatments for severe rare diseases, today announced the appointment of Patrick Malloy as Senior Vice President, Investor Relations and Strategic Communications. Mr. Malloy’s two decades of investor relations and business leadership experience strengthen VectivBio as it continues to evolve into a fully integrated rare disease leader.

“Pat has extensive experience not only in investor relations, but also in commercial and strategic leadership in the areas of biotechnology and rare diseases,” said Luca Santarelli, MD, founder and CEO of VectivBio. “As we prepare for the key catalysts ahead, Pat’s leadership will be instrumental in raising the profile of VectivBio among members of the financial community as we continue to advance our lead candidate’s clinical program. -experimental drug, apraglutide, for the treatment of short bowel syndrome with intestinal disorders. failure.”

Patrick Malloy said: “VectivBio is making tremendous progress in developing innovative therapies to improve the lives of people with serious and debilitating rare diseases. I’m thrilled to join the exceptional team at VectivBio on their journey to deliver potentially game-changing medicines to those who need them most.

Mr. Malloy joins VectivBio after more than four years at Arena Pharmaceuticals, recently acquired by Pfizer, where he served as Vice President of Investor Relations and Corporate Communications. Prior to joining Arena, Mr. Malloy spent over 16 years at Actelion Pharmaceuticals (acquired by Johnson and Johnson in June 2017) where he held several commercial and corporate strategic leadership positions within the organization. Mr. Malloy will be based in the United States and will provide VectivBio with more immediate access to major investors.

About VectivBio AG

VectivBio (Nasdaq: VECT) is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with serious rare diseases. Our lead product candidate, apraglutide, is a next-generation GLP-2 analog currently in a global Phase 3 clinical trial for short bowel syndrome with intestinal failure (SBS-IF). It is being developed for a range of rare gastrointestinal diseases where GLP-2 plays a central role in disease pathophysiology, including acute graft versus host disease (aGVHD).

With the CoMET platform, VectivBio aims to treat serious and often fatal inherited metabolic diseases (IMDs) in pediatric populations. IMDs represent a group of genetic disorders in which dysregulated co-enzyme A (CoA) metabolism is a factor. Candidates from the CoMET platform are initially evaluated in methylmalonic acidemia (MMA) and propionic acidemia (PA). Additional targets include urea cycle disorders, fatty acid oxidation disorders and amino acidopathies.

Learn more about www.vectivbio.comand follow us on LinkedIn and Twitter.

Forward-looking statements:

Forward-looking statements are statements that are not historical facts. Words and phrases such as “expected”, “forward”, “will”, “could”, “could”, “stay”, “potential”, “prepare”, “planned”, “believe”, “plan” , “near future”, “belief”, “guidance” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding the Company’s plans regarding the use of funds from the credit facility with Kreos Capital and its partnership agreement with Asahi Kasei Pharma Corporation, and the outlook for the apraglutide and its Comet platform, as well as potential upcoming data readouts from its clinical trials. All such statements are subject to risks and uncertainties, many of which are difficult to predict and generally beyond VectivBio’s control, which could cause actual results to differ materially from those expressed, implied or projected by the forward-looking statements. These risks and uncertainties include, but are not limited to: the impacts of the Russian-Ukrainian war and the ongoing COVID-19 pandemic, including interruptions or other adverse effects on clinical trials and delays in regulatory review; delay or inability to obtain regulatory approval of VectivBio’s product candidates and successful compliance with FDA and other governmental regulations applicable to product approvals; risks inherent in developing drugs and conducting clinical trials; and the risks and uncertainties identified in the “Risk Factors” section of VectivBio’s Annual Report for the year ending December 31, 2021 on Form 20-F filed with the Securities and Exchange Commission on April 7, 2022. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, VectivBio undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.


patrick malloy
VectivBio SVP, Investor Relations and Strategic Communications

Comments are closed.